Tulinercept Biosimilar – Anti-TNF fusion protein – Research Grade

Description of Tulinercept Biosimilar - Anti-TNF fusion protein - Research Grade

Tulinercept Biosimilar: A Promising Anti-TNF Fusion Protein for Therapeutic Targeting

Tulinercept Biosimilar is a novel biologic drug that has gained significant attention in the field of immunology and biotechnology. It is an anti-tumor necrosis factor (TNF) fusion protein that has shown promising results in pre-clinical studies for the treatment of various inflammatory and autoimmune diseases. In this article, we will discuss the structure, activity, and potential applications of Tulinercept Biosimilar in detail.

Structure of Tulinercept Biosimilar

Tulinercept Biosimilar is a recombinant fusion protein that consists of two components – a soluble TNF receptor (TNFR) and a human IgG1 Fc domain. The TNFR component is derived from the extracellular domain of human TNFR1, which is responsible for binding to TNF. The Fc domain, on the other hand, is responsible for extending the half-life of the drug and enhancing its stability. The two components are linked together by a flexible linker, resulting in a single molecule with a molecular weight of approximately 150 kDa.

The structure of Tulinercept Biosimilar is similar to that of the approved biologic drug, Etanercept, which is used for the treatment of various inflammatory diseases. However, Tulinercept Biosimilar has a higher binding affinity for TNF and a longer half-life, making it a potentially more effective and convenient treatment option.

Activity of Tulinercept Biosimilar

The primary mechanism of action of Tulinercept Biosimilar is to bind and neutralize TNF, a pro-inflammatory cytokine that plays a crucial role in the pathogenesis of many autoimmune and inflammatory diseases. TNF is known to induce the production of other inflammatory cytokines, activate immune cells, and promote tissue damage, making it a prime therapeutic target for these conditions.

Tulinercept Biosimilar works by binding to TNF and preventing it from interacting with its receptors on immune cells. This leads to a decrease in the production of inflammatory cytokines and a reduction in immune cell activation, ultimately resulting in a decrease in disease symptoms and progression.

Potential Applications of Tulinercept Biosimilar

Tulinercept Biosimilar has shown promising results in pre-clinical studies for the treatment of various inflammatory and autoimmune diseases, including rheumatoid arthritis, psoriasis, Crohn’s disease, and ulcerative colitis. It has also been studied for its potential in treating other conditions such as ankylosing spondylitis, juvenile idiopathic arthritis, and psoriatic arthritis.

In addition to its potential as a therapeutic drug, Tulinercept Biosimilar also has potential applications in research and diagnostic settings. Its high binding affinity for TNF makes it a valuable tool for studying the role of TNF in various diseases and for developing diagnostic assays to measure TNF levels in patient samples.

Conclusion

Tulinercept Biosimilar is a promising anti-TNF fusion protein with a unique structure and mechanism of action. It has the potential to be a more effective and convenient treatment option for various inflammatory and autoimmune diseases, and its applications in research and diagnostics make it a versatile and valuable drug. Further clinical studies are needed to fully understand its safety and efficacy, but the early results are promising, and Tulinercept Biosimilar has the potential to make a significant impact in the field of immunology and biotechnology.

Tulinercept Biosimilar - Anti-TNF fusion protein binds to TNFa / TNF-alpha, N-His, recombinant protein in indirect ELISA Assay

Immobilized TNFa / TNF-alpha, N-His, recombinant protein (cat. No.PX-P5961) at 0.5µg/mL (100µL/well) can bind to Tulinercept Biosimilar - Anti-TNF fusion protein (cat. No.PX-TA2023) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450